Showing 6321-6330 of 8201 results for "".
- China's NMPA Accepts Akeso’s NDA for Ebdarokimab in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/chinas-nmpa-accepts-akesos-nda-for-ebdarokimab-in-moderate-to-severe-plaque-psoriasis/2461958/Akeso Inc.’s New Drug Application (NDA) for its fully human IgG1monoclonal antibody ebdarokimab (IL-12/lL-23, AK101) for the treatment of adults with moderate-to-severe plaque psoriasis has been accepted by the National Center for Drug Evaluation of the State Drug Administration of the
- Verrica Pharmaceuticals Update: Company Announces First Sale of YCANTH to FFF Enterpriseshttps://practicaldermatology.com/news/verrica-pharmaceuticals-update-company-announces-first-sale-of-ycanth-to-fff-enterprises/2461957/Verrica Pharmaceuticals Inc. announced the first commercial sale of YCANTH to its exclusive distributor, FFF Enterprises Inc. (FFF). “As one of the nation’s most trusted specialty pharmaceutical distributors, FFF is well positioned to help Verrica introduce YCANTH&trad
- Cutera, Inc. Appoints Jeff Jones as COOhttps://practicaldermatology.com/news/cutera-inc-appoints-jeff-jones-as-coo/2461956/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- Verrica Supports FDA’s Warning Letters to Retailers Selling Unapproved Molluscum Contagiosum Treatmentshttps://practicaldermatology.com/news/verrica-supports-fdas-warning-letters-to-retailers-selling-unapproved-molluscum-contagiosum-treatments/2461954/Verrica Pharmaceuticals Inc. supports the U.S. Food and Drug Administration’s (FDA’s) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum. “On the heels of the June 1, 2023 FDA warning to consumers not to
- Unpacking the AAD’s Updated Guidelines for Managing AD With Topical Therapies in Adultshttps://practicaldermatology.com/news/guideline-author-dr-robert-sidbury-talks-to-dermwire-about-the-new-recommendations/2461953/Despite the availability of systemic medication to treat atopic dermatitis (AD), topical treatments remain mainstays, and new ones have come to market in recent years. To keep pace with the changes, the American Academy of Dermatology (AAD) updated its 2014 guidelines for managing atopi
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- Sentient’s Tixel Receives FDA Nod for Treatment of Periorbital Wrinkleshttps://practicaldermatology.com/news/sentients-tixel-receives-fda-nod-for-treatment-of-periorbital-wrinkles/2461945/The device combines heat with the forward motion of a medical-grade titanium tip. The U.S. Food and Drug Administration has approved
- Business News: LEO Pharma to Acquire Timber Pharmaceuticalshttps://practicaldermatology.com/news/business-news-leo-pharma-to-acquire-timber-pharmaceuticals/2461943/LEO Pharma is set to acquire Timber Pharmaceuticals, Inc. The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million, and up to an additional $22.0 million in contingent value rights payable upon achievement o
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- US FDA Nod for Generic Protopichttps://practicaldermatology.com/news/us-fda-nod-for-generic-protopic/2461939/The United States Food & Drug Administration (FDA) has approved Tacrolimus Ointment, 0.03%, Glenmark Pharmaceuticals’ generic version of Protopic Ointment, 0.03%. Glenmark's Tacrolimus Ointment, 0.03%, will be distributed in the U.S. by Glenmark Pharma